Insulin Peglispro
From PeptidePlaza, the free peptide reference · Entry #1231 · Metabolic · Sources fetched 2026-09-11 · Editorial standards
Insulin Peglispro is a metabolic research peptide. Insulin Peglispro is a long-acting insulin analog that acts as an insulin receptor agonist, developed for the treatment of both type 1 and type 2 diabetes mellitus.
Insulin Peglispro is a modified insulin analog designed to act as an agonist at the insulin receptor. It is characterized by a hepato-preferential action, meaning it has a reduced effect on peripheral tissues compared to other insulins. This compound has been investigated for its potential in managing type 1 and type 2 diabetes mellitus, reaching Phase 3 clinical trials. Research has focused on comparing its efficacy and safety profile against existing basal insulins like insulin glargine, particularly concerning its impact on cardiovascular events and insulin sensitivity.
1 Mechanism of action
Insulin receptor agonist (agonist)
Primary targets: Insulin receptor
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
3 Chemical and physical properties
| Purity (typical) | Not independently verified |
|---|---|
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | Insulin receptor |
4 Research studies (8)
- Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action
Diabetes, obesity & metabolism (2016) · Review - Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial
Diabetes, obesity & metabolism (2016) · RCT - Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis
Cardiovascular diabetology (2016) · Meta-Analysis - Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects
Diabetes care (2014) · RCT - Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes
Diabetes, obesity & metabolism (2017) · RCT - Open-label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin-naïve Asian patients with type 2 diabetes
Journal of diabetes investigation (2018) · RCT - In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog
The Journal of pharmacology and experimental therapeutics (2016) - How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
Diabetes therapy : research, treatment and education of diabetes and related disorders (2017) · Review
5 Safety and risk profile
5.1 Regulatory status
Insulin Peglispro is currently classified as Phase 3 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is Insulin Peglispro?
- Insulin Peglispro is a long-acting insulin analog. It functions as an insulin receptor agonist, meaning it activates insulin receptors to help regulate blood glucose levels. It is designed with a hepato-preferential action.
- What is Insulin Peglispro used for?
- Insulin Peglispro has been studied for the treatment of type 1 diabetes mellitus and type 2 diabetes mellitus. It aims to provide basal insulin support for individuals with these conditions.
- How does Insulin Peglispro work?
- Insulin Peglispro works by acting as an agonist at the insulin receptor. This activation helps to facilitate glucose uptake and utilization by cells, thereby lowering blood glucose. It is noted for its preferential action on the liver compared to peripheral tissues.
- What is the regulatory status of Insulin Peglispro?
- Insulin Peglispro has advanced to Phase 3 clinical trials for both type 1 and type 2 diabetes mellitus, indicating it has undergone extensive testing in human subjects.
7 References
- Insulin Peglispro — molecule record ChEMBL. View source
- Insulin Peglispro — published literature (40 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Insulin Peglispro.
Also targets Insulin receptor
Insulin Glargine is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved to improve glycemic control in patients with type 1 and type 2 diabetes mellitus.
Also targets Insulin receptor
Insulin Aspart is a rapid-acting human insulin analog that functions as an insulin receptor agonist, primarily used to improve glycemic control in patients with diabetes mellitus.
Also targets Insulin receptor
Insulin Lispro, also known as Lyumjev, is a rapid-acting human insulin analog that acts as an insulin receptor agonist.
Also targets Insulin receptor
Insulin Degludec is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved for improving glycemic control in adults with type 2 diabetes mellitus.
Also targets Insulin receptor
Insulin Detemir, also known as Levemir, is a long-acting human insulin analog and an insulin receptor agonist used to improve glycemic control in patients with diabetes mellitus.
Also targets Insulin receptor
Insulin Zinc is an insulin receptor agonist that is FDA-approved for medical use.